Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

FDMT. – 4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc.
FDMT
$3.71
Name : 4D Molecular Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $171,864,272.00
EPSttm : -3.18
finviz dynamic chart for FDMT
4D Molecular Therapeutics, Inc.
$3.71
3.39%
$0.13

Float Short %

10.04

Margin Of Safety %

Put/Call OI Ratio

0.12

EPS Next Q Diff

-0.08

EPS Last/This Y

-0.58

EPS This/Next Y

-0.32

Price

3.71

Target Price

29.56

Analyst Recom

1.82

Performance Q

2.2

Relative Volume

0.4

Beta

2.82

Ticker: FDMT




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02FDMT3.740.170.004211
2025-06-03FDMT3.870.170.004211
2025-06-04FDMT3.830.170.004239
2025-06-05FDMT3.90.170.004268
2025-06-06FDMT4.340.170.034290
2025-06-09FDMT4.780.180.004141
2025-06-10FDMT4.480.180.014137
2025-06-11FDMT4.370.180.254131
2025-06-12FDMT4.510.180.074182
2025-06-13FDMT4.40.180.004249
2025-06-16FDMT4.360.190.004149
2025-06-17FDMT4.160.190.004149
2025-06-18FDMT4.070.190.004147
2025-06-20FDMT4.140.190.004149
2025-06-23FDMT3.770.130.003785
2025-06-24FDMT40.130.003786
2025-06-25FDMT4.10.120.003881
2025-06-26FDMT4.070.120.063981
2025-06-27FDMT3.850.12999.994299
2025-06-30FDMT3.710.12999.994299
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02FDMT3.73-10.0- -3.56
2025-06-03FDMT3.87-10.0- -3.56
2025-06-04FDMT3.84-10.0- -3.56
2025-06-05FDMT3.91-10.0- -3.56
2025-06-06FDMT4.35-10.0- -3.56
2025-06-09FDMT4.79-9.9- -3.56
2025-06-10FDMT4.47-9.9- -3.56
2025-06-11FDMT4.36-9.9- -3.56
2025-06-12FDMT4.50-9.9- -3.56
2025-06-13FDMT4.41-9.9- -3.56
2025-06-16FDMT4.36-9.9- -3.56
2025-06-17FDMT4.14-9.9- -3.56
2025-06-18FDMT4.09-9.9- -3.56
2025-06-20FDMT4.13-9.9- -3.56
2025-06-23FDMT3.76-9.9- -3.56
2025-06-24FDMT4.01-9.9- -3.56
2025-06-25FDMT4.10-9.9- -3.56
2025-06-26FDMT4.06-9.9- -3.56
2025-06-27FDMT3.85-9.9- -3.56
2025-06-30FDMT3.71-9.9- -3.56
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02FDMT0.00-8.5811.24
2025-06-03FDMT0.00-8.5811.24
2025-06-04FDMT0.00-8.5811.24
2025-06-05FDMT0.00-8.5811.24
2025-06-06FDMT0.00-8.5811.24
2025-06-09FDMT0.00-8.5411.24
2025-06-11FDMT0.00-8.5410.48
2025-06-12FDMT0.00-8.5410.48
2025-06-13FDMT0.00-8.5410.48
2025-06-16FDMT0.00-8.5010.48
2025-06-17FDMT0.00-8.5010.48
2025-06-18FDMT0.00-8.5010.48
2025-06-19FDMT0.00-8.5010.48
2025-06-20FDMT0.00-8.5010.48
2025-06-24FDMT0.00-8.5010.48
2025-06-25FDMT0.00-8.5010.48
2025-06-26FDMT0.00-8.5010.04
2025-06-27FDMT0.00-8.5010.04
2025-06-30FDMT0.00-8.4910.04
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.86

Avg. EPS Est. Current Quarter

-0.69

Avg. EPS Est. Next Quarter

-0.94

Insider Transactions

Institutional Transactions

-8.49

Beta

2.82

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

20

Growth Score

31

Sentiment Score

22

Actual DrawDown %

93.3

Max Drawdown 5-Year %

Target Price

29.56

P/E

Forward P/E

PEG

P/S

8593.38

P/B

0.37

P/Free Cash Flow

EPS

-3.37

Average EPS Est. Cur. Y​

-3.56

EPS Next Y. (Est.)

-3.88

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-767126.09

Relative Volume

0.4

Return on Equity vs Sector %

-61.4

Return on Equity vs Industry %

-42.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

4D Molecular Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 227
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.
stock quote shares FDMT. – 4D Molecular Therapeutics Inc Stock Price stock today
news today FDMT. – 4D Molecular Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FDMT. – 4D Molecular Therapeutics Inc yahoo finance google finance
stock history FDMT. – 4D Molecular Therapeutics Inc invest stock market
stock prices FDMT premarket after hours
ticker FDMT fair value insiders trading